HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCPC Sees Opportunity For US Cosmetics Modernization After Congressional Mid-Terms

Executive Summary

The Personal Care Products Council is pivoting to focus on passing cosmetics modernization legislation after mid-term congressional elections, while still hopeful the language could go through as part of FDA user-fee reauthorization. Karin Ross, executive VP, government affairs at PCPC, discussed the situation at the trade group’s Leadership Summit in Washington.

You may also be interested in...



Compliance Clock Starts Ticking Under Historic Modernization of Cosmetic Regulations Act

Companies have one year to comply with US FDA registration and product listing requirements under the Modernization of Cosmetic Regulations Act of 2022, part of the $1.7tr omnibus spending package signed by President Joe Biden on 29 December. Trade groups applauded the historic milestone and the legislation’s departure from previous proposals, including the elimination of user fees.

Cosmetics Reform In, Dietary Supplements Out Of US Omnibus Spending Bill

The must-pass federal spending bill includes the Modernization of Cosmetics Regulation Act, which previously appeared as a rider in US Food and Drug Administration user-fee legislation but was cut from the final iteration.

Former US FDA Heads Urge Congress: Seize Opportunity For Cosmetic, Dietary Supplement Reform

Calling Congress’s failure to include cosmetic and dietary supplement riders in recent FDA user-fee reauthorization “a profound missed opportunity,” former FDA commissioners push for movement in the lame duck Congress in December.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel